---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021868"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:45:28.681620+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics Q3 net loss $84.2M ($0.76/sh); RLY-4008 88% ORR in FGFR2-fusion CCA

## Summary
- Net loss $84.2M vs $60.8M YoY; R&D expenses rose to $66.9M from $45.0M.
- Cash and investments $1.1B as of Sep 30, 2022; sufficient to fund operations into 2025.
- RLY-4008 interim data: 88% ORR at pivotal dose in FGFRi-naive FGFR2-fusion cholangiocarcinoma (n=17).
- Raised $300M gross proceeds in follow-on public offering during Q3.
- RLY-2608 (PI3Kα inhibitor) continues enrolling in single-agent and combination cohorts.

## SEC filing metadata
- accession: 0000950170-22-021868
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017022021868/0000950170-22-021868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017022021868/rlay-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021868
- JSON: https://secwatch.observer/filing/0000950170-22-021868.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021868.txt

## Key facts
- Earnings Releases
  Relay Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $84.2 million for the third quarter of 2022, or a net loss per share of $0.76, EPS $0.76.
  - Period: the quarter ended September 30, 2022
  - Net income: Net loss was $84.2 million for the third quarter of 2022, or a net loss per share of $0.76
  - EPS: $0.76
  - Result: reported results
  source text: Relay Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1812364/000095017022021868/0000950170-22-021868-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.